<DOC>
	<DOC>NCT02499263</DOC>
	<brief_summary>This is a prospective, single country, multi-center study in Ulcerative Colitis (UC) patients treated with adalimumab. 200 subjects will be enrolled at approximately 20 sites. The baseline assessment should be performed prior to the first dose of adalimumab (Visit1). Study visits will be conducted at weeks 8, 16, 24, 32, 40, 48 and 56 in accordance with clinical practice. All subjects will have one Follow-up for safety approximately 70 days after the last dose of adalimumab</brief_summary>
	<brief_title>A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice</brief_title>
	<detailed_description>This is Observation study.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must be an adult &gt;= 19 years Subject with active moderatetosevere ulcerative colitis patients with Mayo score of â‰¥ 6 points and endoscopic subscore of &gt;= 2 points despite treatment with corticosteroids and/or immunosuppressants Subjects must have tuberculosis (TB) Screening Assessment in accordance Korean reimbursement guideline Subjects who are started on adalimumab treatment in normal clinical practice setting Subject must provide written authorization form to use personal and/or health data prior to the entry into the study Female subjects who are pregnant or breast feeding Subject applies with any contraindication to adalimumab Subject is participating in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adalimumab trough level</keyword>
	<keyword>Fecal Calprotectin</keyword>
	<keyword>Fecal microbiota</keyword>
</DOC>